Joseph Anthony Dottino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2024 | 4903 | 1.230 |
Why?
|
| Endometrial Neoplasms | 4 | 2023 | 1379 | 1.080 |
Why?
|
| Endometrial Hyperplasia | 1 | 2023 | 101 | 0.800 |
Why?
|
| Drug Labeling | 1 | 2020 | 251 | 0.560 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2016 | 30 | 0.520 |
Why?
|
| Levonorgestrel | 1 | 2016 | 76 | 0.520 |
Why?
|
| Premenopause | 1 | 2020 | 1039 | 0.520 |
Why?
|
| Contraceptive Agents, Female | 1 | 2016 | 122 | 0.490 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 581 | 0.480 |
Why?
|
| Models, Economic | 2 | 2016 | 716 | 0.460 |
Why?
|
| Estrogens | 1 | 2020 | 1527 | 0.430 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 388 | 0.400 |
Why?
|
| Drug Approval | 1 | 2019 | 818 | 0.380 |
Why?
|
| Health Expenditures | 1 | 2024 | 2386 | 0.380 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1894 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 2041 | 0.270 |
Why?
|
| Obesity | 3 | 2023 | 13078 | 0.270 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3474 | 0.270 |
Why?
|
| Hospitals | 1 | 2019 | 3887 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 5 | 2020 | 5529 | 0.240 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2235 | 0.240 |
Why?
|
| Indazoles | 1 | 2024 | 303 | 0.200 |
Why?
|
| Phthalazines | 1 | 2024 | 397 | 0.190 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1672 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9372 | 0.180 |
Why?
|
| Ostomy | 1 | 2020 | 34 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 533 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 12235 | 0.160 |
Why?
|
| Splenectomy | 1 | 2020 | 390 | 0.150 |
Why?
|
| Diaphragm | 1 | 2020 | 356 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2893 | 0.140 |
Why?
|
| Endometrium | 1 | 2020 | 405 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2020 | 588 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 552 | 0.130 |
Why?
|
| Indoles | 1 | 2024 | 1832 | 0.130 |
Why?
|
| Pancreatectomy | 1 | 2020 | 821 | 0.120 |
Why?
|
| Piperidines | 1 | 2024 | 1662 | 0.120 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 1238 | 0.120 |
Why?
|
| Female | 16 | 2024 | 396050 | 0.120 |
Why?
|
| Carcinosarcoma | 1 | 2015 | 106 | 0.120 |
Why?
|
| United States | 5 | 2020 | 72896 | 0.110 |
Why?
|
| Piperazines | 1 | 2024 | 2546 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 13635 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2023 | 13041 | 0.100 |
Why?
|
| Markov Chains | 1 | 2015 | 971 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 11205 | 0.090 |
Why?
|
| Intestines | 1 | 2020 | 1907 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6839 | 0.090 |
Why?
|
| Humans | 16 | 2024 | 765823 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 2210 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2015 | 865 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1778 | 0.090 |
Why?
|
| Health Surveys | 1 | 2019 | 4058 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 2003 | 0.080 |
Why?
|
| Aged | 7 | 2024 | 171178 | 0.070 |
Why?
|
| Middle Aged | 7 | 2024 | 223016 | 0.070 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2010 | 329 | 0.070 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2010 | 287 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 1425 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2019 | 10087 | 0.070 |
Why?
|
| Length of Stay | 1 | 2019 | 6485 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5338 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 81505 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 706 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 3237 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15794 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 36375 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 59506 | 0.050 |
Why?
|
| Mass Screening | 1 | 2016 | 5445 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6360 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 41643 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26276 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3539 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7416 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 660 | 0.040 |
Why?
|
| Quality of Life | 1 | 2019 | 13466 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2015 | 233 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 65223 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2024 | 1949 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11855 | 0.030 |
Why?
|
| Polymers | 1 | 2021 | 1623 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 74853 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1444 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2454 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 787 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 2878 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2024 | 3614 | 0.020 |
Why?
|
| Gene Expression | 1 | 2023 | 7581 | 0.020 |
Why?
|
| Propensity Score | 1 | 2018 | 1967 | 0.020 |
Why?
|
| Cisplatin | 1 | 2015 | 1653 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2015 | 1726 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6508 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 223055 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 23707 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 22323 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 1752 | 0.010 |
Why?
|
| Survival Rate | 1 | 2018 | 12821 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12520 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 168730 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2024 | 54798 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 81788 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 21501 | 0.010 |
Why?
|